Tissue factor (TF) expression by tumor cells correlates with metastasis clinically and supports metastasis in experimental settings. However, the precise pathways coupling TF to malignancy remain incompletely defined. Here, we show that clot formation by TF indirectly enhances tumor cell survival after arrest in the lung, during experimental lung metastasis, by recruiting macrophages characterized by CD11b, CD68, F4/80, and CX 3 CR1 (but not CD11c) expression. Genetic or pharmacologic inhibition of coagulation, by either induction of TF pathway inhibitor expression or by treatment with hirudin, respectively, abrogated macrophage recruitment and tumor cell survival. Furthermore, impairment of macrophage function, in either Mac1-deficient mice or in CD11b-diphtheria toxin receptor mice in which CD11b-positive cells were ablated, decreased tumor cell survival without altering clot formation, demonstrating that the recruitment of functional macrophages was essential for tumor cell survival. This effect was independent of NK cells. Moreover, a similar population of macrophages was also recruited to the lung during the formation of a premetastatic niche. Anticoagulation inhibited their accumulation and prevented the enhanced metastasis associated with the formation of the niche. Our study, for the first time, links TF induced coagulation to macrophage recruitment in the metastatic process. (Blood. 2012;119(13): 3164-3175) IntroductionClinical and experimental studies over the past 30 years have established that the coagulation system actively supports tumor progression and metastasis. Consistent with these observations, expression of procoagulants by tumor cells, among them tissue factor (TF), cancer procoagulant, 1 and selectin ligands, correlates with advanced disease and poor outcome for multiple cancer types. 2,3 TF (also known as coagulation factor III or CD142) is the protease receptor that initiates coagulation after injury through the extrinsic pathway. Under normal physiologic conditions, TF expression is limited to extravascular sites that only become exposed to blood after trauma. In this case, the exposed TF binds to and activates the blood-borne coagulation factor FVII, triggering clot formation through a cascade of proteolytic events that results in thrombin formation, activation of platelets, and fibrin deposition. 4 In addition to triggering coagulation, the binding of FVIIa to TF activates intracellular signaling pathways through the TF cytoplasmic domain, by activating G-protein-coupled protease activated receptors (PARs), especially PAR2. 4 These signaling pathways support tumor angiogenesis 5,6 and regulate tumor progression. 7 Intracellular signaling pathways can be distinguished experimentally from the extracellular coagulative roles of TF by specific antibodies 7 or deletion of the cytoplasmic domain that eliminates many forms of TF signaling but still triggers coagulation. 6,8,9 TF enhances tumor growth and angiogenesis, [4][5][6][7]10 and specifically plays an important role in some experiment...
Key Points• Metastatic tumor cell attachment induces endothelial VCAM-1 and VAP-1.• VCAM-1 and VAP-1 promote metastatic tumor cell survival by recruiting myeloid cells, pointing to VAP-1 as a therapeutic target.Pulmonary metastasis is a frequent cause of poor outcome in cancer patients. The formation of pulmonary metastasis is greatly facilitated by recruitment of myeloid cells, which are crucial for tumor cell survival and extravasation. During inflammation, homing of myeloid cells is mediated by endothelial activation, raising the question of a potential role for endothelial activation in myeloid cell recruitment during pulmonary metastasis. Here, we show that metastatic tumor cell attachment causes the induction of the endothelial activation markers vascular cell adhesion molecule-1 (VCAM-1) and vascular adhesion protein-1 (VAP-1). Induction of VCAM-1 is dependent on tumor cell-clot formation, decreasing upon induction of tissue factor pathway inhibitor or treatment with hirudin. Furthermore, inhibition of endothelial activation with a VCAM-1 blocking antibody or a VAP-1 small molecule inhibitor leads to reduced myeloid cell recruitment and diminished tumor cell survival and metastasis without affecting tumor cell adhesion. Simultaneous inhibition of VCAM-1 and VAP-1 does not result in further reduction in myeloid cell recruitment and tumor cell survival, suggesting that both act through closely related mechanisms. These results establish VCAM-1 and VAP-1 as mediators of myeloid cell recruitment in metastasis and identify VAP-1 as a potential target for therapeutic intervention to combat early metastasis. (Blood. 2013;121(16):3289-3297)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.